Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Theragenics Corporation currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. BAEK, JONGHWAN NMN is the busiest examiner for the portfolio, managing 1 pending office action. The presence of this single matter reflects a highly specific current prosecution phase for the company.
With 1 distinct examiner overseeing the current matter, the company's prosecution efforts are concentrated under BAEK, JONGHWAN NMN. The involvement of 1 distinct art unit indicates that the active portfolio is contained within a specific technical group. This concentration suggests that practitioners will interact with a single point of contact for the entirety of the company's current examiner engagement. The 1 pending office action represents the full scope of active matters within this technical field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, JONGHWAN NMN | 1 | 50.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18335342 | PHOTOCURABLE COMPOSITIONS AND METHODS FOR DELIVERING RADIATION TO A SUBJECT | BAEK, JONGHWAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18335342 | PHOTOCURABLE COMPOSITIONS AND METHODS FOR DELIVERING RADIATION TO A SUBJECT | BAEK, JONGHWAN NMN | 1618 | §103§112 | Non-Final OA | — | Pending | Jun 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTheragenics Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jonghwan Nmn Baek has the most, with 1 of Theragenics Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
